{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:33:03Z","timestamp":1790343183567,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Over the history of myelodysplastic neoplasms (MDS), an increasing number of treatment modalities have become available. It is therefore important to assess whether these developments have translated into improved overall survival (OS) for patients. We analyzed data from 1,147 patients in the German MDS registry and observed a progressive improvement in median survival across three diagnostic periods: until 2000 (20 months), 2001\u20132010 (31 months), and after 2011 (57 months). Patients treated with allogeneic stem cell transplantation (SCT) had the best prognosis with a median survival of 108 months. Over time, both the proportion of patients undergoing allogeneic SCT (6.3% vs. 22.1% vs. 40.0%) and the median age at transplantation (36.5 vs. 52 vs. 61 years) increased. Notably, OS also improved among patients treated with best supportive care (BSC) alone (17 vs. 31 vs. 64 months;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Multivariate analysis demonstrated that the period of first diagnosis had an independent positive effect on survival. The underlying reasons for this improvement remain unclear, but a multifactorial origin\u2014including improved supportive measures and greater eligibility for allogeneic SCT\u2014must be considered.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-06736-4","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T01:46:24Z","timestamp":1776044784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Influence of different therapy strategies in patients with myelodysplastic neoplasms (MDS) on overall survival with regard to different decades: data from the German MDS registry"],"prefix":"10.1007","volume":"105","author":[{"given":"Jonas","family":"Welsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Kasprzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Aul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina S.","family":"G\u00f6tze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnd","family":"Nusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Lipke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefani","family":"Parmentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Strupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Nachtkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Kobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Gattermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Germing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"issue":"9936","key":"6736_CR1","first-page":"2239","volume":"383","author":"L Ad\u00e8s","year":"2014","unstructured":"Ad\u00e8s L, Itzykson R, Fenaux P (2014) Myelodysplastic syndromes. Lancet Bd 383(9936):2239\u20132252","journal-title":"Myelodysplastic syndromes. Lancet Bd"},{"issue":"12","key":"6736_CR2","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.leukres.2012.08.007","volume":"36","author":"DP Steensma","year":"2012","unstructured":"Steensma DP (2012) \u201eHistorical perspectives on myelodysplastic syndromes. Leuk Res 36(12):1441\u20131452","journal-title":"Leuk Res"},{"key":"6736_CR3","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng W-J, Choi JK, Colmenero I, Couplan SE, Cross NCP, De Jong D, Elghetany TM, Takahashi E, Emile J-F, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li X-Q, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C and Hochhaus A (2022) The 5th edition of the world health organization classification of haematolymphoid tumours. Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia 36:1703\u20131719","DOI":"10.1038\/s41375-022-01613-1"},{"issue":"6","key":"6736_CR4","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/bjh.16206","volume":"189","author":"P Fenaux","year":"2020","unstructured":"Fenaux P, Platzbecker U, Ad\u00e8s L (2020) \u201eHow we manage adults with myelodysplastic syndrome. Br J Haeematology 189(6):1016\u20131027","journal-title":"Br J Haeematology"},{"issue":"2","key":"6736_CR5","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/ajh.26763","volume":"98","author":"P Vittayawacharin","year":"2023","unstructured":"Vittayawacharin P, Kongtim P, Ciurea SO (2023) \u201eAllogeneic stem cell transplantation for patients with myelodysplastic syndromes. Am J Hematol 98(2):322\u2013337","journal-title":"Am J Hematol"},{"key":"6736_CR6","doi-asserted-by":"crossref","unstructured":"Platzbecker U, Schetelig J, Finke J, Trenschel R, Scott BL, Kobbe G, Schaefer-Eckart K, Bornh\u00e4user M, Itzykson R, Germing U, Beelen D, Ehninger G, Fenaux P, Deeg J, Ad\u00e8s L, German MDS, Study (2012) Allogeneic hematopoietic cell transplantation in patients age 60\u201370 years with de Novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Cooperative transplant study groupfred hutchinson cancer research center und groupe francophone de myelodysplasies. Biol Blood Marrow Transplant 9:1415\u20131421","DOI":"10.1016\/j.bbmt.2012.05.003"},{"key":"6736_CR7","doi-asserted-by":"crossref","unstructured":"Robin M, Porcher R, Ad\u00e8s L, Raffoux E, Michallet M, Fran\u00e7ois S, Cahn JY, Delmer A, Wattel E, Vigouroux S, Bay JO, Cornillon J, Huynh A, Nguyen S, Rubio MT, Vincent L, Maillard N, Charbonnier A, de Latour RP, Reman O, Dombret H, Fenaux P, Soci\u00e9 G (2015) HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome a prospective study on behalf of sfgm-tc and GFM. Leukemia 7:1496\u20131501","DOI":"10.1038\/leu.2015.37"},{"key":"6736_CR8","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1200\/JCO.20.03380","volume":"30","author":"R Nakamura","year":"2021","unstructured":"Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, Leifer E, Tamari R, Mishra A, Maziarz RT, McGuirk J, Westervelt P, Vasu S, Patnaik M, Kamble R, Forman SJ, Sekeres MA, Appelbaum F, Medizabal A, Logan B, Horowitz M, Cutler C (2021) \u201eBiologic assignment trial of Reduced-Intensity hematopoietic cell transplantation based on donor availability in patients 50\u201375 years of age with advanced myelodysplastic syndrome. J Clin Oncology: Official J Am Soc Clin Oncol 30:3328\u20133339","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"6736_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.clml.2015.04.002","volume":"15","author":"B Oran","year":"2015","unstructured":"Oran B (2015) Which patients should undergo allogeneic stem cell transplantation for myelodysplastic syndromes, and when should we do it? Clin Lymphoma Myeloma Leuk 15:43\u201349","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6736_CR10","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1200\/JCO.20.02724","volume":"30","author":"N Kr\u00f6ger","year":"2021","unstructured":"Kr\u00f6ger N, Sockel K, Wolschke C, Bethge W, Schlenk RF, Wolf D, Stadler M, Kobbe G, Wulf G, Bug G, Sch\u00e4fer-Eckart K, Scheid C, Nolte F, Kr\u00f6nke J, Stelljes M, Beelen D, Heinzelmann M, Haase D, Buchner H, Bleckert G, Giagounidis A (2021) Platzbecker, \u201eComparison between 5-Azacytidine treatment and allogeneic Stem-Cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study). J Clin Oncology: Official J Am Soc Clin Oncol 30:3318\u20133327","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"104","key":"6736_CR11","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","volume":"2","author":"CS Cutler","year":"2004","unstructured":"Cutler CS, Lee SJ, Greenberg P, Deeg J, Perez WS, Anasetti C, Bolwell BJ, Cairo MS, Gale RP, Klein JP, Lazarus HM, Liesveld JL, McCarthy PL, Milone GA, Rizzo DJ, Schultz KR, Trigg ME, Keating A, Weisdorf DJ, Antin JH, Horowitz MM (2004) Adecision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood Bd 2(104):579\u2013585","journal-title":"Blood Bd"},{"key":"6736_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bbmt.2008.12.003","volume":"2","author":"DM Oliansky","year":"2009","unstructured":"Oliansky DM, Antin JH, Bennett JM, Deeg J, Engelhard C, Heptinstall KV, de Lima M, Gore SD, Potts RG, Silverman LR, Jonas RB, McCarthy PL, Hahn T (2009) \u201eThe role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biology Blood Marrow Transplantation: J Am Soc Blood Marrow Transplantation 2:137\u2013172","journal-title":"Biology Blood Marrow Transplantation: J Am Soc Blood Marrow Transplantation"},{"key":"6736_CR13","first-page":"409","volume":"7","author":"R Phelan","year":"2002","unstructured":"Phelan R, Chen M, Bupp C, Bolon YT, Broglie L, Brunner-Grady J, Burns LJ, Chhabra S, Christianson D, Cusatis R, Devine SM, D\u2019Souza A, Eapen M, Hamadani M, Hengen M, Lee SJ, Moskop A, Page KM, Pasquini M, P\u00e9rez WS, Riches M, Rizzo D, Saber W, Spellman SR, Stefanski HE, Steinert P, Weisdorf D, Horowitz M, Auletta JJ, Shaw BE, Arora M (2002) Updated trends in hematopoietic cell transplantation in the United States with an additional focus on adolescent and young adult transplantation activity and outcomes. Transplant Cell Ther 7:409","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"6736_CR14","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/17474086.2018.1452611","volume":"5","author":"G Kobbe","year":"2018","unstructured":"Kobbe G, Schroeder T, Haas R (2018) Germing, \u201eThe current and future role of stem cells in myelodysplastic syndrome therapies. Expert Rev Hematol 5(11):411\u2013422","journal-title":"Expert Rev Hematol"},{"issue":"10","key":"6736_CR15","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1182\/blood-2018-10-844696","volume":"133","author":"U Platzbecker","year":"2019","unstructured":"Platzbecker U (2019) Treatment of MDS. Blood Bd 133(10):1096\u20131107","journal-title":"Blood Bd"},{"key":"6736_CR16","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1007\/s00277-025-06485-w","volume":"6","author":"K Rauhe","year":"2025","unstructured":"Rauhe K, Kasprzak A, Schulz F, Nachtkamp K, Strupp C, K\u00fcndgen A, Dietrich S, Mayer K, G\u00f6tze KS, Hofmann W-K, Giagounidis A, Gattermann N, Germing U (2025) Non-curative therapies and their impact on the prognosis of patients with myelodysplastic syndromes- a retrospective matched-pairs analysis. Ann Hematol 6:3281\u20133288","journal-title":"Ann Hematol"},{"issue":"8","key":"6736_CR17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.7326\/M19-0916","volume":"172","author":"E Angelucci","year":"2020","unstructured":"Angelucci E, Li J, Greenberg P, Wu D, Hou M, Horacio Monato Figueroa E, Guadalupe Rodriguez M, Dong X, Ghosh J, Izquierdo M, Garcia-Manero G (2020) Iron chelation in transfusion-dependent patients with low- to intermediate-1-risk myelodysplastic syndromes: a randomized trial. Ann Intern Med 172(8):513\u2013522","journal-title":"Ann Intern Med"},{"key":"6736_CR18","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/ajh.26984","volume":"98","author":"G Garcia-Manero","year":"2023","unstructured":"Garcia-Manero G (2023) \u201eMyelodysplastic syndromes: 2023 update on diagnosis, risk-stratification and management. Am J Hematol 98:1307\u20131325","journal-title":"Am J Hematol"},{"issue":"118","key":"6736_CR19","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","volume":"14","author":"P Fenaux","year":"2011","unstructured":"Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, te Boekhorst P, Sanz G, Cdel Ca\u00f1izo, Guerci-Bresler A, Nilsson L, Platzbecker U, L\u00fcbbert M, Quesnel B, Cazzola M, Ganser A, Bowen D, Schlegelberger B, Aul C, Hellstr\u00f6m-Lindberg E (2011) A randomized phase 3 study of lenalidomide versus placebo in rbc transfusion-dependent patients with low-\/intermediate-1-risk myelodysplastic syndromes with del5q. Blood Bd 14(118):3765\u20133776","journal-title":"Blood Bd"},{"key":"6736_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/ejh.12380","volume":"5","author":"A Giagounidis","year":"2014","unstructured":"Giagounidis A, Mufti GJ, Mittelman M, Sanz G, Platzbecker U, Muus P, Selleslag D, Beyne-Rauzy O, te Boekhorst P, del Ca\u00f1izo C, Guerci-Bresler A, Nilsson L, L\u00fcbbert M, Quesnel B, Ganser A, Bowen D, Schlegelberger B, G\u00f6hring G, Fu T, Benettaib B, Hellstr\u00f6m-Lindberg E (2014) Fenaux, \u201eOutcomes in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. Eur J Haematol 5:429\u2013438","journal-title":"Eur J Haematol"},{"issue":"1","key":"6736_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.leukres.2013.10.013","volume":"38","author":"J Neukirchen","year":"2014","unstructured":"Neukirchen J, Lauseker M, Blum S, Giagounidis A, L\u00fcbbert M, Martino S, Siragusa S, Schlenk RF, Platzbecker U, Hofmann W-K, G\u00f6tze K, Palumbo GA, Magrin S, K\u00fcndgen A, Aul C, Hildebrandt B, Hasford J, Kobbe G, Haas R (2014) Germing, \u201eValidation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study. Leuk Res 38(1):57\u201364","journal-title":"Leuk Res"},{"issue":"29","key":"6736_CR22","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1038\/leu.2015.115","volume":"9","author":"T Bernal","year":"2015","unstructured":"Bernal T, Martinez-Camblor P, Sanchez-Garcia J, de Paz R, Lu\u00f1o E, Nomdedeu B, Ardanaz MT, Pedro C, Amigo ML, Xicoy B, del Ca\u00f1izo C, Tormo M, Bargay J, Valcarcel D, Brunet S, Benlloch L, Sanz G (2015) Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. Leukemia Bd 9(29):1875\u20131881","journal-title":"Leukemia Bd"},{"key":"6736_CR23","doi-asserted-by":"crossref","unstructured":"Ad\u00e8s L (2023) Traitement des syndromes my\u00e9lodysplasiques de haut risque. Bulletin du Cancer 11:1162\u20131167","DOI":"10.1016\/j.bulcan.2023.02.029"},{"issue":"7","key":"6736_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.leukres.2015.04.001","volume":"39","author":"J Neukirchen","year":"2015","unstructured":"Neukirchen J, Nachtkamp K, Schemenau J, Aul C, Giagounidis A, Strupp C, Kuendgen A, Kobbe G, Haas R, Germing U (2015) \u201eChange of prognosis of patients with myelodysplastic syndromes during the last 30 years. Leuk Res 39(7):679\u2013683","journal-title":"Leuk Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06736-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06736-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06736-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:21:51Z","timestamp":1778750511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06736-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["6736"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06736-4","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"239"}}